secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001437749-24-026060
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman
--------------------------------------------------------------------------------

- GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.
- Oversubscribed rights offering generated $60M gross proceeds; warrants could add up to $66M.
- Completed first US soft tissue ablation procedure after FDA clearance; pivotal trial for benign thyroid nodules planned in 2025.
- Received FDA Breakthrough Device Designation for Cardiac Surgery System for AF; first European epicardial ablations completed.
- Appointed Paul LaViolette as Co-Chairman of Board; he brings 40 years medtech experience from Boston Scientific.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/plse20240614_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer